After Hours Top Gainers $SDST $HCAI $YYAI $VCRE $SHFS
Mostrar más$9.440
+0.289 (+3.06%)Al cierre
Loading chart…
- Máximo
- 9.740
- Apertura
- 9.570
- Precio medio ponderado por volumen
- 9.51
- Volumen
- 25.16K
- Capitalización
- —
- Mínimo
- 9.340
- Importe
- 239.20K
- EV/EBITDA, TTM
- 0.00
Vicore Pharma Holding AB is a Sweden-based drug-development company. The Company's portfolio contains small molecules with potential indications, including anti-inflammation, nerve generation and cardiovascular disease. The Company is a wholly owned subsidiary of Mintage Scientific AB.
Análisis de IA of Vicore Pharma Holding AB (VCRE)
ComprarVicore Pharma (VCRE) is a good buy right now due to its favorable technical indicators and positive analyst outlook. The current price is $9.59, significantly below the analyst price target of $25, indicating a potential upside of over 160%. Additionally, the stock has shown a recent 5-day change of +2.02%, suggesting a positive momentum. However, the main risk is the negative net income trend, with a net income loss of -142,844,000 SEK in Q2 2026, which highlights ongoing financial challenges.
Métricas de valoración
El PER previsto actual de Vicore Pharma Holding AB (VCRE) es 0.00, frente a su media de 5 años de .
Preguntas frecuentes sobre VCRE, respondidas por Alphio AI
Vicore Pharma Holding AB is a Sweden-based drug-development company. The Company's portfolio contains small molecules with potential indications, including anti-inflammation, nerve generation and cardiovascular disease. The Company is a wholly owned subsidiary of Mintage Scientific AB. It operates in the Healthcare sector.
Vicore Pharma (VCRE) is a good buy right now due to its favorable technical indicators and positive analyst outlook. The current price is $9.59, significantly below the analyst price target of $25, indicating a potential upside of over 160%. Additionally, the stock has shown a recent 5-day change of +2.02%, suggesting a positive momentum. However, the main risk is the negative net income trend, with a net income loss of -142,844,000 SEK in Q2 2026, which highlights ongoing financial challenges.
Comunidad
Más ↗Artículos relacionados
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.